Glucose Intolerance Clinical Trial
— NPETA-GDOfficial title:
Non-Persistent Environmental Toxicants Avoidance Study for Individuals With Glucose Dysregulation Who Are Not Using Insulin (NPETA-GD)
NCT number | NCT04821752 |
Other study ID # | 20-1672 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 1, 2022 |
Est. completion date | September 1, 2024 |
Verified date | July 2022 |
Source | Bastyr University |
Contact | Amber Coggins |
Phone | 425 602 3000 |
acoggins[@]bastyr.edu | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is designed to test whether non-persistent environmental chemicals (PECs) are elevated in people with glucose dysregulation. The primary aim is to measure whether this toxicant burden can be reduced using a dietary and lifestyle modification intervention. The secondary aim is to observe any changes in glucose response pre and post-intervention.
Status | Recruiting |
Enrollment | 25 |
Est. completion date | September 1, 2024 |
Est. primary completion date | September 1, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: 1. 18 years old or older 2. Able to complete the remote informed consent process. 3. Glucose dysregulation with HbA1c >= 5.7% at baseline 4. If HgA1c is greater than 6.5% and the potential participant is not already receiving standard care for diabetes from a physician, participants must see their primary care provider for diabetes standard care before enrollment in the study. 5. Those not already eating a majority organic-food diet and drinking filtered water (>50% by self-disclosure) Exclusion Criteria 1. Use of insulin or insulin analog medications 2. Planning to have elective surgery, diagnostic procedures, dental, or cosmetic procedures during the study period 3. Unable or unwilling to modify dietary and lifestyle behaviors 4. Those already eating a majority organic-food diet and drinking filtered water (>50% by self-disclosure) |
Country | Name | City | State |
---|---|---|---|
United States | Bastyr University | Kenmore | Washington |
Lead Sponsor | Collaborator |
---|---|
Bastyr University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in percentile score of urinary excretion of toxicant marker metabolites pre and post three-week dietary and lifestyle intervention | The primary aim will be measured using a commercially-available screening test for urinary toxicant metabolites. The toxicant burden will be measured by a percentile score of each metabolite and summing all percentile values. A risk level of each metabolite will be normalized by the percentile score in order to calculate the total toxic burden for an individual. Wilcoxon-ranked sum non-parametric calculations will be used to evaluate whether pre and post-intervention reduction has occurred. Because this is a single-arm trial, any reduction in the toxicant burden will be correlated with the relative improvement of the secondary endpoint and will be measured using Kendall's tau-beta ranked correlation. | 3 months | |
Secondary | Change in immediate glucose response measured by daily fasting and post-prandial blood glucose measurements. | A secondary endpoint is to observe each participant's glucose response throughout the 3-week trial period. Because this is not powered, the estimated mean reduction from the baseline to the ending of the trial cannot be estimated. Any reduction in the blood glucsoe mean values allows us to calculate the effect size for future investigation. The ranking of the improvement in glucose response (smaller AUC) is tested with the ranking of the reduction of toxic burden by a correlation analysis described the above. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT03241121 -
Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome
|
N/A | |
Completed |
NCT03809182 -
Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels.
|
Phase 4 | |
Completed |
NCT03675360 -
Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial
|
N/A | |
Completed |
NCT01671293 -
Multicomponent Telecare Model for Supporting Prediabetes Patients
|
N/A | |
Not yet recruiting |
NCT01402362 -
Prevalence of Glucose Intolerance and Risk Factors in Ethiopian Immigrants in Israel; Follow-up Study.
|
N/A | |
Completed |
NCT00740363 -
Sitagliptin in Renal Transplant Recipients
|
Phase 4 | |
Completed |
NCT00436475 -
Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT04090788 -
The Effect of Momordica Charantia Supplementation on Blood Glucose Levels
|
N/A | |
Active, not recruiting |
NCT05460884 -
Effects of Seaweed Extract on Postprandial Response to White Bread
|
N/A | |
Not yet recruiting |
NCT05462834 -
Impact of Nocturnal Hypoxemia on Glucose in High Altitude Sleep Disordered Breathing
|
N/A | |
Completed |
NCT03348020 -
Iron and Insulin Resistance in Overweight and Obese Humans
|
N/A | |
Terminated |
NCT03356873 -
Impact of Correction of Vitamin D Deficiency in Oxidative Stress in Patients With Prediabetes (VICOX)
|
N/A | |
Completed |
NCT03922685 -
Effects of Diet and Exercise on Circadian Glycemia
|
N/A | |
Completed |
NCT03730727 -
Exercise-meal Timing and Postprandial Glucose Control
|
N/A | |
Completed |
NCT04743960 -
Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition
|
N/A | |
Completed |
NCT04004273 -
Diabetes, Exercise and Liver Fat (DELIVER)
|
N/A | |
Terminated |
NCT01887691 -
Sleep Effectiveness and Insulin and Glucose Homeostasis
|
Phase 1 | |
Completed |
NCT02412995 -
The Effects of Sea Buckthorn and Strawberry on Postprandial Glycaemia, Insulinemia and Appetite
|
Phase 0 | |
Not yet recruiting |
NCT01436448 -
Probiotics (Lactobacillus Rhamnosus) in Reducing Glucose Intolerance During and After Pregnancy
|
Phase 3 |